INCY News and Press, Incyte Corporation From 08/06/23

2023-08-06 17:35:15 ET More on the markets Charts Say Pullback Should Be Followed By Higher Highs SPY: It's Time To Book Some Profits (Technical Analysis, Rating Downgrade) 3 Reasons Why SPY Could Be On The Cusp Of A Bear Market Roth MKM still sees recession ...

2023-08-01 11:50:03 ET Incyte Corporation (INCY) Q2 2023 Earnings Call Transcript July 31, 2023 08:00 AM ET Company Participants Greg Shertzer - Investor Relations Herve Hoppenot - President and Chief Executive Officer Pablo Cagnoni - President, Head of Research ...

2023-08-01 07:04:04 ET Incyte press release ( NASDAQ: INCY ): Q2 Non-GAAP EPS of $0.99 beats by $0.12 . Revenue of $954.61M (+4.7% Y/Y) beats by $44.2M . Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi (ruxoli...

Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023 Opzelura ...

Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280 Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic...

2023-07-31 13:10:06 ET Incyte ( NASDAQ: INCY ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is $0.87 (-13.9% Y/Y) and the consensus Revenue Estimate is $910.41M (-0.1% Y/Y). Over the last 2 years, I...

2023-07-28 05:31:08 ET Summary Arcutis has launched Zoryve, a topical cream for the treatment of psoriasis, and is focused on transitioning to a commercial-stage company. The company has made progress with major pharmacy benefit managers and positioned Zoryve to be highly accessib...

2023-07-25 10:44:53 ET Incyte: Growing Strong But Overhyped Incyte: The Jakafi Company Branching Out - Baby Steps For further details see: Incyte a new buy at Citi on Opzelura performance

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease PR Newswire – Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg admi...

2023-07-11 17:08:02 ET Gainers: Incyte  ( NASDAQ: INCY ) +4% . Veracyte ( VCYT ) +4% . Kronos ( KRON ) +3% . Applied Optoelectronics  ( AAOI ) +3% . GoodRx  ( GDRX ) +3% . Losers: Silk Road  ( SI...